Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)

Journal of Translational Medicine
Paolo A AsciertoMagdalena Thurin

Abstract

Metastatic melanoma represents a challenging clinical situation and, until relatively recently, there was an absence of effective treatment options. However, in 2011, the advanced melanoma treatment landscape was revolutionised with the approval of the anti-cytotoxic T-lymphocyte-associated protein-4 checkpoint inhibitor ipilimumab and the selective BRAF kinase inhibitor vemurafenib, both of which significantly improved overall survival. Since then, availability of new immunotherapies, especially the anti-programmed death-1 checkpoint inhibitors, as well as other targeted therapies, have further improved outcomes for patients with advanced melanoma. Seven years on from the first approval of these novel therapies, evidence for the use of various immune-based and targeted approaches is continuing to increase at a rapid rate. Improved understanding of the tumour microenvironment and tumour immuno-evasion strategies has resulted in different approaches to target and harness the immune response. These new immune-based approaches offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as targeted therapy, electroche...Continue Reading

References

Oct 9, 2007·Cancer Treatment Reviews·Philip LuiThomas R Einarson
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Apr 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Benjamin WeideGraham Pawelec
Aug 30, 2013·Science Translational Medicine·Stefani SprangerThomas F Gajewski
Dec 3, 2013·BMC Cancer·Corrado CaracòPaolo Antonio Ascierto
May 15, 2015·Nature·Stefani SprangerThomas F Gajewski
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert H I AndtbackaRobert S Coffin
Sep 12, 2015·Science·Eliezer M Van AllenLevi A Garraway
Jan 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander MartensBenjamin Weide
May 10, 2016·The Journal of Clinical Investigation·Janice M MehnertShridar Ganesan
May 14, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander MartensBenjamin Weide
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benjamin WeideJedd D Wolchok
Jun 15, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Igor PuzanovRobert H I Andtbacka
Aug 30, 2016·Nature Biotechnology·Amalie Kai BentzenSine Reker Hadrup
Nov 3, 2016·Cancer Immunology Research·Douglas B JohnsonChristine M Lovly
Oct 9, 2016·The New England Journal of Medicine·Alexander M M EggermontAlessandro Testori
Nov 12, 2016·Proceedings of the National Academy of Sciences of the United States of America·Stefani SprangerThomas F Gajewski
Apr 27, 2017·The Journal of Investigative Dermatology·Shenying FangJeffrey E Lee
Jun 27, 2017·The Journal of Clinical Investigation·Mark AyersTerrill K McClanahan
Jul 12, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Natalie J IvesUNKNOWN International Melanoma Meta-Analysis Collaborative Group (IMMCG)
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin
Sep 12, 2017·The New England Journal of Medicine·Georgina V LongJohn M Kirkwood
Sep 12, 2017·The New England Journal of Medicine·Jeffrey WeberUNKNOWN CheckMate 238 Collaborators
Oct 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason ChesneyHoward L Kaufman
Nov 21, 2017·Journal of the National Cancer Institute·Anshuman PandaShridar Ganesan
Jan 9, 2018·Nature Medicine·Carsten KriegBurkhard Becher
Dec 12, 2017·Emerging Topics in Life Sciences·Rongze LuFrancesco M Marincola

❮ Previous
Next ❯

Citations

Jan 22, 2021·Investigational New Drugs·Giandomenico RovielloNavid Sobhani
Jun 27, 2021·ChemMedChem·Shaymaa Emam Kassab, Samar Mowafy

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
xenograft
exome sequencing

Clinical Trials Mentioned

NCT03335540

Software Mentioned

OncoKB

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.